Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome Y Allory, W Beukers, A Sagrera, M Flández, M Marqués, M Márquez, ... European urology 65 (2), 360-366, 2014 | 298 | 2014 |
Differential requirements for DOCK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing C Nombela-Arrieta, RA Lacalle, MC Montoya, Y Kunisaki, D Megıas, ... Immunity 21 (3), 429-441, 2004 | 267 | 2004 |
Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead L Martínez-Gac, M Marqués, Z García, MR Campanero, AC Carrera Molecular and cellular biology, 2004 | 247 | 2004 |
Phosphoinositide 3‐kinase controls early and late events in mammalian cell division Z García, A Kumar, M Marques, I Cortes, AC Carrera The EMBO journal 25 (4), 655-661, 2006 | 178 | 2006 |
Phosphoinositide 3–kinase γ participates in T cell receptor–induced T cell activation I Alcázar, M Marqués, A Kumar, E Hirsch, M Wymann, AC Carrera, ... The Journal of experimental medicine 204 (12), 2977-2987, 2007 | 125 | 2007 |
Specific function of phosphoinositide 3-kinase beta in the control of DNA replication M Marqués, A Kumar, AM Poveda, S Zuluaga, C Hernández, S Jackson, ... Proceedings of the National Academy of Sciences 106 (18), 7525-7530, 2009 | 104 | 2009 |
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors C Hafner, A Toll, A Fernández-Casado, J Earl, M Marqués, F Acquadro, ... Proceedings of the National Academy of Sciences 107 (48), 20780-20785, 2010 | 102 | 2010 |
The N-terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells A Gubern, M Joaquin, M Marquès, P Maseres, J Garcia-Garcia, R Amat, ... Molecular cell 64 (1), 25-36, 2016 | 94 | 2016 |
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non‐muscle invasive tumors M Duenas, M Martínez‐Fernández, R García‐Escudero, F Villacampa, ... Molecular carcinogenesis 54 (7), 566-576, 2015 | 80 | 2015 |
A PI3K activity‐independent function of p85 regulatory subunit in control of mammalian cytokinesis Z García, V Silio, M Marques, I Cortes, A Kumar, C Hernandez, AI Checa, ... The EMBO journal 25 (20), 4740-4751, 2006 | 79 | 2006 |
Phosphoinositide 3-Kinases p110α and p110β Regulate Cell Cycle Entry, Exhibiting Distinct Activation Kinetics in G1 Phase M Marqués, A Kumar, I Cortés, A Gonzalez-García, C Hernández, ... Molecular and cellular biology 28 (8), 2803-2814, 2008 | 74 | 2008 |
p85β phosphoinositide 3-kinase subunit regulates tumor progression I Cortés, J Sánchez-Ruíz, S Zuluaga, V Calvanese, M Marqués, ... Proceedings of the National Academy of Sciences 109 (28), 11318-11323, 2012 | 71 | 2012 |
Phosphoinositide 3-Kinase Activation in Late G1 Is Required for c-Myc Stabilization and S Phase Entry A Kumar, M Marqués, AC Carrera Molecular and cellular biology 26 (23), 9116-9125, 2006 | 60 | 2006 |
Phosphoinositide 3-kinase and Forkhead, a switch for cell division L Martinez-Gac, B Alvarez, Z Garcia, M Marques, M Arrizabalaga, ... Biochemical Society Transactions 32 (2), 360-361, 2004 | 44 | 2004 |
Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy A Font, M Domènech, R Benítez, M Rava, M Marqués, JL Ramírez, ... Cancers 12 (7), 1784, 2020 | 34 | 2020 |
Choline Kinase Alpha (CHKα) as a therapeutic target in pancreatic ductal adenocarcinoma: Expression, predictive value, and sensitivity to inhibitors JM Mazarico, VJ Sanchez-Arevalo Lobo, R Favicchio, W Greenhalf, ... Molecular cancer therapeutics 15 (2), 323-333, 2016 | 34 | 2016 |
Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features M Marqués, R Tranchant, B Risa-Ebrí, ML Suárez-Solís, LC Fernández, ... Cancer Research 80 (4), 843-856, 2020 | 19 | 2020 |
E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing Á Millán-Uclés, S Zuluaga, M Marqués, J Vallejo-Díaz, L Sanz, ... Oncotarget 7 (51), 84054, 2016 | 11 | 2016 |
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models D Vangala, S Ladigan, ST Liffers, S Noseir, A Maghnouj, TM Götze, ... Genome medicine 13, 1-25, 2021 | 10 | 2021 |
A cascade involving p85, Cdc42 and septin 2 regulates cytokinesis V Silio, M Marques, I Cortes, S Zuluaga, AC Carrera Biochemical Society Transactions 35 (2), 222-224, 2007 | 8 | 2007 |